Literature DB >> 30768909

A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease.

Dave Singh1,2, Rainard Fuhr3, Lali Jimenez4, Ulrika Wählby Hamrén5, Alexandra Jauhiainen5, Marie-Pierre Malice4, Victor Balaguer4, Alejhandra Lei4, Ajay Aggarwal6, Carol Astbury4, Ioannis Psallidas5.   

Abstract

Entities:  

Year:  2019        PMID： 30768909     DOI： 10.1164/rccm.201812-2345LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  4 in total

Review 1.  G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action.

Authors:  Stacy Gelhaus Wendell; Hao Fan; Cheng Zhang
Journal:  Pharmacol Rev       Date:  2020-01       Impact factor: 25.468

2.  Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.

Authors:  Dave Singh; Victor Balaguer; Carol Astbury; Ulrika Wählby-Hamrén; Eulalia Jimenez; Beatriz Seoane; Cristina Villarroel; Alejhandra Lei; Ajay Aggarwal; Ioannis Psallidas
Journal:  Respir Res       Date:  2020-09-09

3.  Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.

Authors:  Victor Balaguer; Muna Albayaty; Eulalia Jimenez; Ulrika Wählby-Hamrén; Carol Astbury; Beatriz Seoane; Marie-Pierre Malice; Alejhandra Lei; Ajay Aggarwal; Ioannis Psallidas
Journal:  Respir Res       Date:  2020-09-09

Review 4.  Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease.

Authors:  Josuel Ora; Angelo Coppola; Mario Cazzola; Luigino Calzetta; Paola Rogliani
Journal:  J Exp Pharmacol       Date:  2020-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.